Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randy F Sweis

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Cancer Immunology Research|September 6, 2018
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy SelectionJonathan A Trujillo, Randy F Sweis, Riyue Bao, et al.
Cureus|March 31, 2016
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung CancerRandy F Sweis, Sachdev Thomas, Bruce Bank, et al.
Iscience|May 31, 2022
A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissuesDaniel Bergman, Randy F Sweis, Alexander T Pearson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2019
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human CancersJason J Luke, Riyue Bao, Randy F Sweis, et al.
Human Pathology|September 28, 2020
Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomiesLisa Han, Alexander J Gallan, Gary D Steinberg, et al.
Cancers|January 11, 2022
Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma-A ReviewArman S Walia, Randy F Sweis, Piyush K Agarwal, et al.
Computational and Systems Oncology|January 5, 2022
A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancerKamaldeen Okuneye, Daniel Bergman, Jeffrey C Bloodworth, et al.
Scientific Reports|December 18, 2023
Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanismsYixuan Wang, Daniel R Bergman, Erica Trujillo, et al.
Journal for Immunotherapy of Cancer|March 13, 2019
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapyCraig Labbate, Ken Hatogai, Ryan Werntz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2024
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate CancerKunal B Desai, Anthony V Serritella, Walter M Stadler, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Cancer Immunology Research|September 6, 2018
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy SelectionJonathan A Trujillo, Randy F Sweis, Riyue Bao, et al.
Cureus|March 31, 2016
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung CancerRandy F Sweis, Sachdev Thomas, Bruce Bank, et al.
Iscience|May 31, 2022
A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissuesDaniel Bergman, Randy F Sweis, Alexander T Pearson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2019
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human CancersJason J Luke, Riyue Bao, Randy F Sweis, et al.
Human Pathology|September 28, 2020
Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomiesLisa Han, Alexander J Gallan, Gary D Steinberg, et al.
Cancers|January 11, 2022
Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma-A ReviewArman S Walia, Randy F Sweis, Piyush K Agarwal, et al.
Computational and Systems Oncology|January 5, 2022
A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancerKamaldeen Okuneye, Daniel Bergman, Jeffrey C Bloodworth, et al.
Scientific Reports|December 18, 2023
Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanismsYixuan Wang, Daniel R Bergman, Erica Trujillo, et al.
Journal for Immunotherapy of Cancer|March 13, 2019
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapyCraig Labbate, Ken Hatogai, Ryan Werntz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2024
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate CancerKunal B Desai, Anthony V Serritella, Walter M Stadler, et al.
Pageof 6